Is hyperprogressive disease a specific phenomenom of immunotherapy?

Area of Science:

• Oncology
• Immunotherapy Research

Background:

• Hyperprogressive disease (HPD) represents a novel and concerning pattern of response observed during cancer immunotherapy.
• The prevalence of HPD has been investigated across different cancer types, with a particular focus on non-small cell lung cancer, using varied definition criteria.

Purpose of the Study:

• To summarize existing data on hyperprogressive disease (HPD) in the context of various cancer treatments.
• To explore whether HPD is an inherent phenomenon of immunotherapy or associated with specific treatment modalities.

Main Methods:

• Systematic review of retrospective studies evaluating HPD prevalence.
• Analysis of studies examining HPD across diverse cancer types and treatment regimens.

Main Results:

• Data on HPD prevalence and characteristics in various cancers are summarized.
• The association between HPD and immunotherapy is critically examined based on current literature.

Conclusions:

• Hyperprogressive disease (HPD) is a recognized phenomenon in cancer immunotherapy.
• Further research is needed to fully understand the mechanisms and clinical implications of HPD across different cancer treatments.